Atlas Venture’s Post

One month to go before our round table discussion debating cell and gene vs. small molecule therapies. Really looking forward to advocating for biotech approaches for curing disease. We are living in an exciting time with medical breakthroughs seemingly every day. If you would like to join us, take a look at the below links. #cellandgenetherapy #pharmaceuticals #biotech #ipstrategy

Editas Medicine (NASDAQ: EDIT) and CRISPR Therapeutics (NASDAQ: CRSP) share more than a few similarities despite being at different stages of the biotech lifecycle. Both companies are betting that their acumen with gene editing will enable them to make therapies that were impossible to conceive of just a few years ago, and they're both aiming for the same disease markets. https://lnkd.in/dfNWvrXk

Congratulations on promising pre-clinical results! Now, the challenge lies in translating success to the clinical realm. The landscape of AAV characterization studies and understanding manufacturing impurities poses evolving regulatory questions. Drug developers are increasingly prioritizing early manufacturing quality assessments in pre-clinical development. Read along to learn the essential steps for characterizing your gene therapy product with bioreactor simulator runs in your pre-clinical development stage. https://hubs.li/Q02kzPjm0 #GeneTherapy #PersonalizedMedicine #AAV

Cell and gene therapy (CAGT) is following a rapid upwards trajectory, but the best methods for post-trial long-term follow-up (LTFU) are still evolving. With the FDA and EMA issuing guidelines for the design and key data elements of required LTFU studies for CAGT, IQVIA Biotech’s Erin Finot, MS, MBA and IQVIA’s Barbara Isquith Arone, MS consider how best to meet them head-on. Read now. https://bit.ly/49ckYm4 #biotech #genetherapy #CAGT #celltherapy #clinicaltrials

🚀 REGENXBIO Inc. has initiated patient enrollment for a new cohort in their Phase I/II AFFINITY DUCHENNE® trial, focusing on evaluating RGX-202, an innovative gene therapy for boys aged 1-3 with Duchenne muscular dystrophy (Duchenne). Key Updates: - Enrollment for patients aged 1-3 years has begun. - End-of-Phase II meeting with the FDA scheduled for late July to finalize the pivotal trial design. - RGX-202, with unique features, is the only gene therapy in development for Duchenne that incorporates the C-Terminal domain. - The pivotal trial initiation is on track for late Q3 to early Q4 2024. - RGX-202 aims to meet the high unmet need in the Duchenne community. This significant step marks progress towards rapidly advancing RGX-202 to the pivotal stage and future commercialization. #GeneTherapy #Duchenne #ClinicalTrials #Biotech #Healthcare #Innovation #AAV

For anyone working in cell and gene therapies, I highly recommend giving Scientist.com's latest article on streamlining IND applications a read! 🧬 This article offers a glimpse into how Scientist.com helps researchers efficiently manage IND applications for CGTs—from preclinical to clinical and CMC processes. We should be doing everything we can to accelerate bringing high-quality life-changing therapies to the clinic, and Scientist.com is playing a huge role in that. 🔗 Read more here: https://lnkd.in/e42ujB7N #CellTherapy #GeneTherapy #IND #RegulatoryAffairs #CMC #FasterScience

Cell and gene therapy (CAGT) is following a rapid upwards trajectory, but the best methods for post-trial long-term follow-up (LTFU) are still evolving. With the FDA and EMA issuing guidelines for the design and key data elements of required LTFU studies for CAGT, IQVIA Biotech’s Erin Finot, MS, MBA and IQVIA’s Barbara Isquith Arone, MS consider how best to meet them head-on. Read now. https://bit.ly/4aiyd6o #biotech #genetherapy #CAGT #celltherapy #clinicaltrials

Cell and gene therapy (CAGT) is following a rapid upwards trajectory, but the best methods for post-trial long-term follow-up (LTFU) are still evolving. With the FDA and EMA issuing guidelines for the design and key data elements of required LTFU studies for CAGT, IQVIA Biotech’s Erin Finot, MS, MBA and IQVIA’s Barbara Isquith Arone, MS consider how best to meet them head-on. Read now. https://bit.ly/3Wm3As1 #biotech #genetherapy #CAGT #celltherapy #clinicaltrials

🚀 The Spark of Curiosity: Our Infinite Journey of Discovery 🌟 "The creation of new knowledge starts from the spark of curiosity to seek explanations and then you find more knowledge." — David Deutsch, The Beginning of Infinity In our fast-paced world, it's easy to overlook the fundamental driver of progress: curiosity. It's this insatiable desire to understand, to question, and to explore that fuels innovation and propels us forward. Every breakthrough, every leap in technology, and every scientific discovery starts with a simple question: Why? How? What if? From these questions, we embark on a journey of exploration, uncovering new insights and expanding our horizons. David Deutsch beautifully encapsulates this endless cycle in his book, reminding us that our potential for growth is boundless. Each new piece of knowledge we gain is not an endpoint but a stepping stone to further inquiry and discovery. As we navigate our careers and personal lives, let's embrace our inner curiosity. Let’s ask more questions, seek deeper explanations, and remain open to the infinite possibilities that lie ahead. After all, the journey of knowledge is infinite, and it all begins with that first spark of curiosity. Here's to a future where we never stop learning and discovering! 🌐💡 #West #Innovation #Curiosity #Knowledge #Learning #Progress

This article underscores the growing prominence of cell and gene therapy in the pharmaceutical industry, recognizing both its potential and challenges in the evolving landscape of healthcare innovation. This aligns seamlessly with my clients' scientific organization, currently experiencing substantial growth. The importance of team training in the cell and gene therapy industry lies in the need for a skilled and adaptable workforce. Continuous education and skill development empower professionals to address challenges, capitalize on opportunities, and contribute to the growth and success of the CGT sector. #atmps #cellandgenetherapy #learninganddevelopment #teamtraining